93 related articles for article (PubMed ID: 34937858)
1. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Mellinghoff SC; Robrecht S; Mayer L; Weskamm LM; Dahlke C; Gruell H; Vanshylla K; Schlösser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
Leukemia; 2022 Feb; 36(2):562-565. PubMed ID: 34937858
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Mellinghoff SC; Mayer L; Robrecht S; Weskamm LM; Dahlke C; Gruell H; Schlotz M; Vanshylla K; Schloser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
Haematologica; 2022 Oct; 107(10):2480-2484. PubMed ID: 35734927
[No Abstract] [Full Text] [Related]
3. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.
Lyski ZL; Kim MS; Xthona Lee D; Raué HP; Raghunathan V; Griffin J; Ryan D; Brunton AE; Curlin ME; Slifka MK; Messer WB; Spurgeon SE
Blood Adv; 2022 Feb; 6(4):1207-1211. PubMed ID: 34872103
[No Abstract] [Full Text] [Related]
4. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
[No Abstract] [Full Text] [Related]
5. SARS-CoV-2 vaccination in CLL: how often is enough?
Mellinghoff SC; Cornely OA
Blood; 2022 Dec; 140(25):2655-2657. PubMed ID: 36548017
[No Abstract] [Full Text] [Related]
6. Vaccination against COVID-19: a challenge in CLL.
Eichhorst B
Blood; 2021 Jun; 137(23):3153-3154. PubMed ID: 34110406
[No Abstract] [Full Text] [Related]
7. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
[TBL] [Abstract][Full Text] [Related]
8. Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
Ujjani C; Greninger AL; Shadman M; Hill JA; Lynch RC; Warren EH; Gopal AK
Am J Hematol; 2022 Feb; 97(2):E67-E69. PubMed ID: 34807468
[No Abstract] [Full Text] [Related]
9. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
10. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
11. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Cuneo A; Rigolin GM; Coscia M; Quaresmini G; Scarfò L; Mauro FR; Motta M; Quaglia FM; Trentin L; Ferrario A; Laurenti L; Reda G; Ferrari A; Pietrasanta D; Sportoletti P; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; Farina L; Del Poeta G; Varettoni M; Chiurazzi F; Marasca R; Malerba L; Ibatici A; Tisi MC; Stefoni V; Leone M; Baratè C; Olivieri J; Murru R; Gentile M; Sanna A; Gozzetti A; Gattei V; Gottardi D; Derenzini E; Levato L; Orsucci L; Penna G; Chiarenza A; Foà R
Hematol Oncol; 2021 Oct; 39(4):570-574. PubMed ID: 34258787
[No Abstract] [Full Text] [Related]
12. Vaccinations in CLL: implications for COVID-19.
Shadman M; Ujjani C
Blood; 2021 Jan; 137(2):144-146. PubMed ID: 33443562
[No Abstract] [Full Text] [Related]
13. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
Shen Y; Freeman JA; Holland J; Solterbeck A; Naidu K; Soosapilla A; Downe P; Tang C; Kerridge I; Wallman L; Van Bilsen N; Milogiannakis V; Akerman A; Martins Costa Gomes G; Sandgren K; Cunningham AL; Turville S; Mulligan SP
Br J Haematol; 2022 Apr; 197(1):41-51. PubMed ID: 34962656
[TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
16. Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia.
Favresse J; Eucher C; Elsen M; Graux C; Goebels P; Laffineur K; Nicolas JB; Dogné JM; Douxfils J
Br J Haematol; 2020 Aug; 190(4):e187-e189. PubMed ID: 32557555
[No Abstract] [Full Text] [Related]
17. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
Del Poeta G; Laureana R; Bomben R; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Nunzi A; Postorino M; Pasqualone G; Brisotto G; Steffan A; Muraro E; Zucchetto A; Del Principe MI; Gattei V
Hematol Oncol; 2023 Aug; 41(3):559-562. PubMed ID: 36585917
[No Abstract] [Full Text] [Related]
19. Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection, and change to single-dose vaccination.
Mungmunpuntipantip R; Wiwanitkit V
J Med Virol; 2021 Dec; 93(12):6474. PubMed ID: 34374991
[No Abstract] [Full Text] [Related]
20. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.
Khayat-Khoei M; Conway S; Rubinson DA; Jarolim P; Houtchens MK
J Neurol; 2021 Oct; 268(10):3592-3594. PubMed ID: 33638680
[No Abstract] [Full Text] [Related]
[Next] [New Search]
